|
Status |
Public on May 20, 2012 |
Title |
Gene expression profile of U373MG exposed to anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids (I) |
Sample type |
RNA |
|
|
Source name |
U373MG cells treated with DMSO as a control for ET-770
|
Organism |
Homo sapiens |
Characteristics |
cell line: U373MG cell type: glioblastoma treatment: dimethyl sulfoxide (DMSO) for 24 hours at a concentration equivalent to ET-770
|
Treatment protocol |
The cells were exposed to dimethyl sulfoxide (DMSO) for 24 hours at a concentration equivalent to ET-770.
|
Growth protocol |
The cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin (feeding medium).
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated from the cells by using the TRIZOL Plus RNA Purification kit (Invitrogen).
|
Label |
biotin
|
Label protocol |
Three hundred ng of total RNA was processed for cRNA synthesis, fragmentation, and terminal labeling with the GeneChip Whole Transcript Sense Target Labeling and Control Reagents (Affymetrix).
|
|
|
Hybridization protocol |
Hybridization was performed at 45℃ for 17 hours. The arrays were washed and stained in the GeneChip Fluidic Station 450 (Affymetrix) by using Hybridization, Wash and Stain kit (Affymetrix).
|
Scan protocol |
The arrays were scanned by the GeneChip Scanner 3000 7G (Affymetrix).
|
Data processing |
The data expressed as CEL files were normalized by the robust multiarray average (RMA) method with the Expression Console software (Affymetrix).
|
|
|
Submission date |
Mar 20, 2012 |
Last update date |
May 20, 2012 |
Contact name |
Jun-ichi Satoh |
E-mail(s) |
[email protected]
|
Organization name |
Meiji Pharmaceutical University
|
Department |
Bioinformatics
|
Lab |
Molecular Neuropathology
|
Street address |
2-522-1 Noshio, Kiyose
|
City |
Tokyo |
ZIP/Postal code |
204-8588 |
Country |
Japan |
|
|
Platform ID |
GPL6244 |
Series (1) |
GSE36619 |
Gene expression profile of U373MG exposed to novel anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids |
|